Medy-Tox Inc. (KOSDAQ:086900)

South Korea · Delayed Price · Currency is KRW

73,000

+4,100 (5.95%)

Sep 1, 2026, 3:30 PM KST

-38.71% (1Y)

Market Cap	449.06B -46.3%
Revenue (ttm)	251.08B +7.0%
Net Income	14.34B -20.2%
EPS	2,237.82 -21.2%
Shares Out	6.52M
PE Ratio	30.79
Forward PE	15.82
Dividend	1,200.00 (1.78%)
Ex-Dividend Date	Sep 29, 2025

Volume	39,797
Open	69,100
Previous Close	68,900
Day's Range	69,100 - 73,000
52-Week Range	65,600 - 141,100
Beta	0.42
Analysts	Hold
Price Target	99,500.00 (+36.3%)
Earnings Date	Nov 13, 2026

About Medy-Tox

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hya... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2000

Employees 703

Stock Exchange KOSDAQ

Ticker Symbol 086900

Full Company Profile

Financial Performance

In 2025, Medy-Tox's revenue was 247.29 billion, an increase of 8.17% compared to the previous year's 228.62 billion. Earnings were 15.62 billion, a decrease of -2.26%.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for 086900 stock is "Hold." The 12-month stock price target is ₩99,500, which is an increase of 36.30% from the latest price.

Price Target

₩99,500

(36.30% upside)

Analyst Consensus: Hold

Stock Forecasts